Abstract
Prospective reports suggest metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) is associated with improved treatment outcomes. When the addition of androgen-deprivation therapy (ADT) to MDT for omCSPC is needed is unclear. Here we assess the ability of an androgen receptor activity (AR-A) signature to provide prognostic information for omCSPC patients treated with MDT without and with ADT.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
